- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04782375
Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B (ADAPT)
A Multicenter Prospective Open-label Single Arm Trial to Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B With a Comparison to Matched Historical Controls (ADAPT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This clinical trial is a multicenter, Prospective Open-label Single Arm Trial to compare the short-term clinical outcome between stopping and continuing antiviral treatment in chronic hepatitis B patients without cirrhosis who are currently HBV DNA (-) and HBeAg (-) Approximately 140 subjects meeting eligibility criteria will be enrolled a Intervention Arm as below;
- Intervention Arm: 140 subjects, discontinue antiviral treatment (stop group)
- Historical cohort: 700 subjects, continue antiviral treatment
Stop group is scheduled to be followed up to 6months. Patients in the stop group were retreated with nucleos(t)ide analogues that had been prescribed previously if they fulfill one of the following criteria: 1) HBV DNA >2,000 IU/mL, 2) progression to liver cirrhosis, or 3) development of hepatocellular carcinoma.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Daegu, Korea, Republic of
- Kyungpook National University Hospital
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Chung-Ang University Hospital
-
Seoul, Korea, Republic of
- Korea University Guro Hospital
-
Seoul, Korea, Republic of
- Konkuk University Hospital
-
Seoul, Korea, Republic of
- Kyung-Hee University Hospital
-
Ulsan, Korea, Republic of
- Ulsan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and able to provide written informed consent prior to study entry
- Age ≥19 years and ≤65 years at the time of screening
- HBsAg titer <3,000 IU/mL at the time of screening
- Antiviral treatment continued at least 2 years and HBeAg (-) at the time of screening
- Undetectable HBV DNA level at the time of screening
- Serum ALT level <80 IU/mL at the time of screening
- Estimated creatinine clearance ≥30 ml/min (by calculation of creatinine clearance or using the CKD-EPI equation)
- Ability to comply with all study requirements
Exclusion Criteria:
- Confirmed known co-infection with HCV, HIV, or HDV
- Evidence of liver cirrhosis defined as meeting any of the following criteria:
- Current alcohol (60g/day) or substance abuse judged by the investigator that will potentially interfere with subject compliance (1) Splenomegaly (>12 cm) assessed by ultrasound, CT, or MRI (2) Fibroscan ≥9.0 kPa (3) Platelet count <150,000/mm3 However, if the above criteria were satisfied at the time of antiviral treatment initiation, subjects may be eligible if they have low possibility of having liver cirrhosis with improvement in liver function by long-term antiviral treatment, following the opinion of the investigator.
- Any history of clinical hepatic decompensation (e.g., ascites, encephalopathy, variceal hemorrhage) within 12 months prior to the screening or Child-Pugh score of ≥7 at the time of screening
- Currently on or have received therapy with Interferon or immunosuppressant (including systemic chemotherapy) within 12 months prior to the screening
- Requirement for chronic use of systemic immunosuppressant including, but not limited to, corticosteroid (prednisone equivalent of >40 mg/day for >2 weeks), azathioprine, or monoclonal antibodies
- Received solid organ or bone marrow transplant
- Any other clinical conditions (cardiovascular, respiratory, neurologic, or renal conditions) or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.
- History or current evidence of hepatocellular carcinoma (HCC), or high α-fetoprotein (AFP) > 20 ng/mL. (But, the patients with AFP > 20 ng/mL can be enrolled and there is no evidence of HCC by dynamic CT or MRI perfomred within 4 months prior to the screening)
- Malignancy other than hepatocellular carcinoma within the 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (within 2 years prior to screening with confirmation of no evidence of disease). Subjects under evaluation for possible malignancy are not eligible.
- Concurrent enrollment in another clinical study for other type of antiviral treatment for CHB or immune modulatory drug within 3 months prior to Screening, participation to an observational (non-interventional) clinical studies or interventional studies not using anti-HBV or immune modulatory drugs, or during the follow-up period of an interventional study are not exclusion criteria.
- Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm A
discontinue antiviral treatment
|
discontinue antiviral treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
virological relapse
Time Frame: Change from baseline in HBV DNA result at 6month
|
Proportion of virological relapse defined as HBV DNA ≥2,000 IU/mL
|
Change from baseline in HBV DNA result at 6month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hospital admission
Time Frame: From baseline, clinical events will be collected within 6month
|
Proportion of liver-related unexpected hospital admission
|
From baseline, clinical events will be collected within 6month
|
Proportion of clinical relapse
Time Frame: at 6 month
|
Proportion of clinical relapse (HBV DNA ≥2,000 IU/mL and ALT ≥80 IU/mL)
|
at 6 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Young-Suk Lim, PhD, Asan Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Chronic Disease
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Anti-Infective Agents
- Antiviral Agents
Other Study ID Numbers
- AMC 2021-0135
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
Clinical Trials on Stop group
-
University Hospital Inselspital, BerneUniversity of Lausanne Hospitals; Triemli Hospital; Kantonsspital Chur, SwitzerlandCompletedMortality | Incidence of Surgical Site Infection | Short Intraoperative Briefings | Shared Mental ModelSwitzerland
-
Chinese Academy of Medical Sciences, Fuwai HospitalUnknownCoronary Artery Disease | Aortic Atherosclerotic DiseaseChina
-
Chinese Academy of Medical Sciences, Fuwai HospitalUnknownCoronary Artery Disease | Aortic Atherosclerotic DiseaseChina
-
University of PotsdamCompletedAbdominal Pain | Functional Abdominal Pain SyndromeGermany
-
Akdeniz UniversityThe Scientific and Technological Research Council of TurkeyRecruitingChild | Parents | Urine | Exposure to Environmental Pollution | Second Hand SmokeTurkey
-
University of Kansas Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruiting
-
University of Colorado, DenverActive, not recruitingChronic Pain | Opioid-use DisorderUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingDifficult Intubation | Airway DiseaseTurkey
-
Aalborg University HospitalCompletedGraves Disease | Hyperthyroidism
-
Medtronic Spine LLCWithdrawnLumbar Spinal Stenosis